Global Neuroprotective Drugs Market Growth 2025-2031
The global Neuroprotective Drugs market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
Neuroprotective Drugs consist of medications that can be used to protect or preserve the neuronal cells of the brain from degeneration, stress, and injury, which can impair cognitive functions.
Factors expected to drive market growth include increasing prevalence of neurological disorders. Neurological diseases are the leading cause of disability and death worldwide. The “big three” neurodegenerative diseases: Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis, have resulted in significant increases in morbidity and mortality in the elderly population worldwide. Neuroprotective drugs are those that help maintain the structure and function of neurons. Neuroprotective drugs have the potential to reduce stroke deaths by 6 million per year. According to data updated by the World Health Organization in February 2022, approximately 50 million people worldwide suffer from epilepsy every year.
Alzheimer's disease segment is expected to hold major market share in the neuroprotective agents market
The incidence of Alzheimer's disease has been increasing and is expected to continue to increase in the coming decades. According to statistics from the World Health Organization, nearly 50 million people worldwide were suffering from Alzheimer's disease and other dementias in 2020, and this number is expected to exceed 152 million by 2050. Additionally, Alzheimer's disease progression increases with age and is the fifth largest contributor to the global disease burden, with the global disease burden exceeding 1 Trillions of dollars.
LP Information, Inc. (LPI) ' newest research report, the “Neuroprotective Drugs Industry Forecast” looks at past sales and reviews total world Neuroprotective Drugs sales in 2024, providing a comprehensive analysis by region and market sector of projected Neuroprotective Drugs sales for 2025 through 2031. With Neuroprotective Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Neuroprotective Drugs industry.
This Insight Report provides a comprehensive analysis of the global Neuroprotective Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Neuroprotective Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Neuroprotective Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Neuroprotective Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Neuroprotective Drugs.
This report presents a comprehensive overview, market shares, and growth opportunities of Neuroprotective Drugs market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global Neuroprotective Drugs market?
What factors are driving Neuroprotective Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Neuroprotective Drugs market opportunities vary by end market size?
How does Neuroprotective Drugs break out by Type, by Application?
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
Neuroprotective Drugs consist of medications that can be used to protect or preserve the neuronal cells of the brain from degeneration, stress, and injury, which can impair cognitive functions.
Factors expected to drive market growth include increasing prevalence of neurological disorders. Neurological diseases are the leading cause of disability and death worldwide. The “big three” neurodegenerative diseases: Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis, have resulted in significant increases in morbidity and mortality in the elderly population worldwide. Neuroprotective drugs are those that help maintain the structure and function of neurons. Neuroprotective drugs have the potential to reduce stroke deaths by 6 million per year. According to data updated by the World Health Organization in February 2022, approximately 50 million people worldwide suffer from epilepsy every year.
Alzheimer's disease segment is expected to hold major market share in the neuroprotective agents market
The incidence of Alzheimer's disease has been increasing and is expected to continue to increase in the coming decades. According to statistics from the World Health Organization, nearly 50 million people worldwide were suffering from Alzheimer's disease and other dementias in 2020, and this number is expected to exceed 152 million by 2050. Additionally, Alzheimer's disease progression increases with age and is the fifth largest contributor to the global disease burden, with the global disease burden exceeding 1 Trillions of dollars.
LP Information, Inc. (LPI) ' newest research report, the “Neuroprotective Drugs Industry Forecast” looks at past sales and reviews total world Neuroprotective Drugs sales in 2024, providing a comprehensive analysis by region and market sector of projected Neuroprotective Drugs sales for 2025 through 2031. With Neuroprotective Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Neuroprotective Drugs industry.
This Insight Report provides a comprehensive analysis of the global Neuroprotective Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Neuroprotective Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Neuroprotective Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Neuroprotective Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Neuroprotective Drugs.
This report presents a comprehensive overview, market shares, and growth opportunities of Neuroprotective Drugs market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Cholinesterase inhibitors
- Anti-inflammatory
- Others
- Alzheimer's disease
- Parkinson's disease
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Genervon
- NeuroVive Pharmaceutical
- Ceregene
- BHR Pharma
- Neuren Pharmaceuticals
- Allon therapeutics
- Bionure
- AstraZeneca
- Biogen
- Merck KGaA
- Teva Pharmaceutical Industries Ltd
- Novartis
What is the 10-year outlook for the global Neuroprotective Drugs market?
What factors are driving Neuroprotective Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Neuroprotective Drugs market opportunities vary by end market size?
How does Neuroprotective Drugs break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Neuroprotective Drugs Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Neuroprotective Drugs by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Neuroprotective Drugs by Country/Region, 2020, 2024 & 2031
2.2 Neuroprotective Drugs Segment by Type
2.2.1 Cholinesterase inhibitors
2.2.2 Anti-inflammatory
2.2.3 Others
2.3 Neuroprotective Drugs Sales by Type
2.3.1 Global Neuroprotective Drugs Sales Market Share by Type (2020-2025)
2.3.2 Global Neuroprotective Drugs Revenue and Market Share by Type (2020-2025)
2.3.3 Global Neuroprotective Drugs Sale Price by Type (2020-2025)
2.4 Neuroprotective Drugs Segment by Application
2.4.1 Alzheimer's disease
2.4.2 Parkinson's disease
2.4.3 Others
2.5 Neuroprotective Drugs Sales by Application
2.5.1 Global Neuroprotective Drugs Sale Market Share by Application (2020-2025)
2.5.2 Global Neuroprotective Drugs Revenue and Market Share by Application (2020-2025)
2.5.3 Global Neuroprotective Drugs Sale Price by Application (2020-2025)
3 GLOBAL BY COMPANY
3.1 Global Neuroprotective Drugs Breakdown Data by Company
3.1.1 Global Neuroprotective Drugs Annual Sales by Company (2020-2025)
3.1.2 Global Neuroprotective Drugs Sales Market Share by Company (2020-2025)
3.2 Global Neuroprotective Drugs Annual Revenue by Company (2020-2025)
3.2.1 Global Neuroprotective Drugs Revenue by Company (2020-2025)
3.2.2 Global Neuroprotective Drugs Revenue Market Share by Company (2020-2025)
3.3 Global Neuroprotective Drugs Sale Price by Company
3.4 Key Manufacturers Neuroprotective Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Neuroprotective Drugs Product Location Distribution
3.4.2 Players Neuroprotective Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR NEUROPROTECTIVE DRUGS BY GEOGRAPHIC REGION
4.1 World Historic Neuroprotective Drugs Market Size by Geographic Region (2020-2025)
4.1.1 Global Neuroprotective Drugs Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Neuroprotective Drugs Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Neuroprotective Drugs Market Size by Country/Region (2020-2025)
4.2.1 Global Neuroprotective Drugs Annual Sales by Country/Region (2020-2025)
4.2.2 Global Neuroprotective Drugs Annual Revenue by Country/Region (2020-2025)
4.3 Americas Neuroprotective Drugs Sales Growth
4.4 APAC Neuroprotective Drugs Sales Growth
4.5 Europe Neuroprotective Drugs Sales Growth
4.6 Middle East & Africa Neuroprotective Drugs Sales Growth
5 AMERICAS
5.1 Americas Neuroprotective Drugs Sales by Country
5.1.1 Americas Neuroprotective Drugs Sales by Country (2020-2025)
5.1.2 Americas Neuroprotective Drugs Revenue by Country (2020-2025)
5.2 Americas Neuroprotective Drugs Sales by Type (2020-2025)
5.3 Americas Neuroprotective Drugs Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Neuroprotective Drugs Sales by Region
6.1.1 APAC Neuroprotective Drugs Sales by Region (2020-2025)
6.1.2 APAC Neuroprotective Drugs Revenue by Region (2020-2025)
6.2 APAC Neuroprotective Drugs Sales by Type (2020-2025)
6.3 APAC Neuroprotective Drugs Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Neuroprotective Drugs by Country
7.1.1 Europe Neuroprotective Drugs Sales by Country (2020-2025)
7.1.2 Europe Neuroprotective Drugs Revenue by Country (2020-2025)
7.2 Europe Neuroprotective Drugs Sales by Type (2020-2025)
7.3 Europe Neuroprotective Drugs Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Neuroprotective Drugs by Country
8.1.1 Middle East & Africa Neuroprotective Drugs Sales by Country (2020-2025)
8.1.2 Middle East & Africa Neuroprotective Drugs Revenue by Country (2020-2025)
8.2 Middle East & Africa Neuroprotective Drugs Sales by Type (2020-2025)
8.3 Middle East & Africa Neuroprotective Drugs Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Neuroprotective Drugs
10.3 Manufacturing Process Analysis of Neuroprotective Drugs
10.4 Industry Chain Structure of Neuroprotective Drugs
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Neuroprotective Drugs Distributors
11.3 Neuroprotective Drugs Customer
12 WORLD FORECAST REVIEW FOR NEUROPROTECTIVE DRUGS BY GEOGRAPHIC REGION
12.1 Global Neuroprotective Drugs Market Size Forecast by Region
12.1.1 Global Neuroprotective Drugs Forecast by Region (2026-2031)
12.1.2 Global Neuroprotective Drugs Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Neuroprotective Drugs Forecast by Type (2026-2031)
12.7 Global Neuroprotective Drugs Forecast by Application (2026-2031)
13 KEY PLAYERS ANALYSIS
13.1 Genervon
13.1.1 Genervon Company Information
13.1.2 Genervon Neuroprotective Drugs Product Portfolios and Specifications
13.1.3 Genervon Neuroprotective Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Genervon Main Business Overview
13.1.5 Genervon Latest Developments
13.2 NeuroVive Pharmaceutical
13.2.1 NeuroVive Pharmaceutical Company Information
13.2.2 NeuroVive Pharmaceutical Neuroprotective Drugs Product Portfolios and Specifications
13.2.3 NeuroVive Pharmaceutical Neuroprotective Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 NeuroVive Pharmaceutical Main Business Overview
13.2.5 NeuroVive Pharmaceutical Latest Developments
13.3 Ceregene
13.3.1 Ceregene Company Information
13.3.2 Ceregene Neuroprotective Drugs Product Portfolios and Specifications
13.3.3 Ceregene Neuroprotective Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Ceregene Main Business Overview
13.3.5 Ceregene Latest Developments
13.4 BHR Pharma
13.4.1 BHR Pharma Company Information
13.4.2 BHR Pharma Neuroprotective Drugs Product Portfolios and Specifications
13.4.3 BHR Pharma Neuroprotective Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 BHR Pharma Main Business Overview
13.4.5 BHR Pharma Latest Developments
13.5 Neuren Pharmaceuticals
13.5.1 Neuren Pharmaceuticals Company Information
13.5.2 Neuren Pharmaceuticals Neuroprotective Drugs Product Portfolios and Specifications
13.5.3 Neuren Pharmaceuticals Neuroprotective Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Neuren Pharmaceuticals Main Business Overview
13.5.5 Neuren Pharmaceuticals Latest Developments
13.6 Allon therapeutics
13.6.1 Allon therapeutics Company Information
13.6.2 Allon therapeutics Neuroprotective Drugs Product Portfolios and Specifications
13.6.3 Allon therapeutics Neuroprotective Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Allon therapeutics Main Business Overview
13.6.5 Allon therapeutics Latest Developments
13.7 Bionure
13.7.1 Bionure Company Information
13.7.2 Bionure Neuroprotective Drugs Product Portfolios and Specifications
13.7.3 Bionure Neuroprotective Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Bionure Main Business Overview
13.7.5 Bionure Latest Developments
13.8 AstraZeneca
13.8.1 AstraZeneca Company Information
13.8.2 AstraZeneca Neuroprotective Drugs Product Portfolios and Specifications
13.8.3 AstraZeneca Neuroprotective Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 AstraZeneca Main Business Overview
13.8.5 AstraZeneca Latest Developments
13.9 Biogen
13.9.1 Biogen Company Information
13.9.2 Biogen Neuroprotective Drugs Product Portfolios and Specifications
13.9.3 Biogen Neuroprotective Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 Biogen Main Business Overview
13.9.5 Biogen Latest Developments
13.10 Merck KGaA
13.10.1 Merck KGaA Company Information
13.10.2 Merck KGaA Neuroprotective Drugs Product Portfolios and Specifications
13.10.3 Merck KGaA Neuroprotective Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 Merck KGaA Main Business Overview
13.10.5 Merck KGaA Latest Developments
13.11 Teva Pharmaceutical Industries Ltd
13.11.1 Teva Pharmaceutical Industries Ltd Company Information
13.11.2 Teva Pharmaceutical Industries Ltd Neuroprotective Drugs Product Portfolios and Specifications
13.11.3 Teva Pharmaceutical Industries Ltd Neuroprotective Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 Teva Pharmaceutical Industries Ltd Main Business Overview
13.11.5 Teva Pharmaceutical Industries Ltd Latest Developments
13.12 Novartis
13.12.1 Novartis Company Information
13.12.2 Novartis Neuroprotective Drugs Product Portfolios and Specifications
13.12.3 Novartis Neuroprotective Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.12.4 Novartis Main Business Overview
13.12.5 Novartis Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Neuroprotective Drugs Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Neuroprotective Drugs by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Neuroprotective Drugs by Country/Region, 2020, 2024 & 2031
2.2 Neuroprotective Drugs Segment by Type
2.2.1 Cholinesterase inhibitors
2.2.2 Anti-inflammatory
2.2.3 Others
2.3 Neuroprotective Drugs Sales by Type
2.3.1 Global Neuroprotective Drugs Sales Market Share by Type (2020-2025)
2.3.2 Global Neuroprotective Drugs Revenue and Market Share by Type (2020-2025)
2.3.3 Global Neuroprotective Drugs Sale Price by Type (2020-2025)
2.4 Neuroprotective Drugs Segment by Application
2.4.1 Alzheimer's disease
2.4.2 Parkinson's disease
2.4.3 Others
2.5 Neuroprotective Drugs Sales by Application
2.5.1 Global Neuroprotective Drugs Sale Market Share by Application (2020-2025)
2.5.2 Global Neuroprotective Drugs Revenue and Market Share by Application (2020-2025)
2.5.3 Global Neuroprotective Drugs Sale Price by Application (2020-2025)
3 GLOBAL BY COMPANY
3.1 Global Neuroprotective Drugs Breakdown Data by Company
3.1.1 Global Neuroprotective Drugs Annual Sales by Company (2020-2025)
3.1.2 Global Neuroprotective Drugs Sales Market Share by Company (2020-2025)
3.2 Global Neuroprotective Drugs Annual Revenue by Company (2020-2025)
3.2.1 Global Neuroprotective Drugs Revenue by Company (2020-2025)
3.2.2 Global Neuroprotective Drugs Revenue Market Share by Company (2020-2025)
3.3 Global Neuroprotective Drugs Sale Price by Company
3.4 Key Manufacturers Neuroprotective Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Neuroprotective Drugs Product Location Distribution
3.4.2 Players Neuroprotective Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR NEUROPROTECTIVE DRUGS BY GEOGRAPHIC REGION
4.1 World Historic Neuroprotective Drugs Market Size by Geographic Region (2020-2025)
4.1.1 Global Neuroprotective Drugs Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Neuroprotective Drugs Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Neuroprotective Drugs Market Size by Country/Region (2020-2025)
4.2.1 Global Neuroprotective Drugs Annual Sales by Country/Region (2020-2025)
4.2.2 Global Neuroprotective Drugs Annual Revenue by Country/Region (2020-2025)
4.3 Americas Neuroprotective Drugs Sales Growth
4.4 APAC Neuroprotective Drugs Sales Growth
4.5 Europe Neuroprotective Drugs Sales Growth
4.6 Middle East & Africa Neuroprotective Drugs Sales Growth
5 AMERICAS
5.1 Americas Neuroprotective Drugs Sales by Country
5.1.1 Americas Neuroprotective Drugs Sales by Country (2020-2025)
5.1.2 Americas Neuroprotective Drugs Revenue by Country (2020-2025)
5.2 Americas Neuroprotective Drugs Sales by Type (2020-2025)
5.3 Americas Neuroprotective Drugs Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Neuroprotective Drugs Sales by Region
6.1.1 APAC Neuroprotective Drugs Sales by Region (2020-2025)
6.1.2 APAC Neuroprotective Drugs Revenue by Region (2020-2025)
6.2 APAC Neuroprotective Drugs Sales by Type (2020-2025)
6.3 APAC Neuroprotective Drugs Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Neuroprotective Drugs by Country
7.1.1 Europe Neuroprotective Drugs Sales by Country (2020-2025)
7.1.2 Europe Neuroprotective Drugs Revenue by Country (2020-2025)
7.2 Europe Neuroprotective Drugs Sales by Type (2020-2025)
7.3 Europe Neuroprotective Drugs Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Neuroprotective Drugs by Country
8.1.1 Middle East & Africa Neuroprotective Drugs Sales by Country (2020-2025)
8.1.2 Middle East & Africa Neuroprotective Drugs Revenue by Country (2020-2025)
8.2 Middle East & Africa Neuroprotective Drugs Sales by Type (2020-2025)
8.3 Middle East & Africa Neuroprotective Drugs Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Neuroprotective Drugs
10.3 Manufacturing Process Analysis of Neuroprotective Drugs
10.4 Industry Chain Structure of Neuroprotective Drugs
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Neuroprotective Drugs Distributors
11.3 Neuroprotective Drugs Customer
12 WORLD FORECAST REVIEW FOR NEUROPROTECTIVE DRUGS BY GEOGRAPHIC REGION
12.1 Global Neuroprotective Drugs Market Size Forecast by Region
12.1.1 Global Neuroprotective Drugs Forecast by Region (2026-2031)
12.1.2 Global Neuroprotective Drugs Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Neuroprotective Drugs Forecast by Type (2026-2031)
12.7 Global Neuroprotective Drugs Forecast by Application (2026-2031)
13 KEY PLAYERS ANALYSIS
13.1 Genervon
13.1.1 Genervon Company Information
13.1.2 Genervon Neuroprotective Drugs Product Portfolios and Specifications
13.1.3 Genervon Neuroprotective Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Genervon Main Business Overview
13.1.5 Genervon Latest Developments
13.2 NeuroVive Pharmaceutical
13.2.1 NeuroVive Pharmaceutical Company Information
13.2.2 NeuroVive Pharmaceutical Neuroprotective Drugs Product Portfolios and Specifications
13.2.3 NeuroVive Pharmaceutical Neuroprotective Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 NeuroVive Pharmaceutical Main Business Overview
13.2.5 NeuroVive Pharmaceutical Latest Developments
13.3 Ceregene
13.3.1 Ceregene Company Information
13.3.2 Ceregene Neuroprotective Drugs Product Portfolios and Specifications
13.3.3 Ceregene Neuroprotective Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Ceregene Main Business Overview
13.3.5 Ceregene Latest Developments
13.4 BHR Pharma
13.4.1 BHR Pharma Company Information
13.4.2 BHR Pharma Neuroprotective Drugs Product Portfolios and Specifications
13.4.3 BHR Pharma Neuroprotective Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 BHR Pharma Main Business Overview
13.4.5 BHR Pharma Latest Developments
13.5 Neuren Pharmaceuticals
13.5.1 Neuren Pharmaceuticals Company Information
13.5.2 Neuren Pharmaceuticals Neuroprotective Drugs Product Portfolios and Specifications
13.5.3 Neuren Pharmaceuticals Neuroprotective Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Neuren Pharmaceuticals Main Business Overview
13.5.5 Neuren Pharmaceuticals Latest Developments
13.6 Allon therapeutics
13.6.1 Allon therapeutics Company Information
13.6.2 Allon therapeutics Neuroprotective Drugs Product Portfolios and Specifications
13.6.3 Allon therapeutics Neuroprotective Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Allon therapeutics Main Business Overview
13.6.5 Allon therapeutics Latest Developments
13.7 Bionure
13.7.1 Bionure Company Information
13.7.2 Bionure Neuroprotective Drugs Product Portfolios and Specifications
13.7.3 Bionure Neuroprotective Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Bionure Main Business Overview
13.7.5 Bionure Latest Developments
13.8 AstraZeneca
13.8.1 AstraZeneca Company Information
13.8.2 AstraZeneca Neuroprotective Drugs Product Portfolios and Specifications
13.8.3 AstraZeneca Neuroprotective Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 AstraZeneca Main Business Overview
13.8.5 AstraZeneca Latest Developments
13.9 Biogen
13.9.1 Biogen Company Information
13.9.2 Biogen Neuroprotective Drugs Product Portfolios and Specifications
13.9.3 Biogen Neuroprotective Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 Biogen Main Business Overview
13.9.5 Biogen Latest Developments
13.10 Merck KGaA
13.10.1 Merck KGaA Company Information
13.10.2 Merck KGaA Neuroprotective Drugs Product Portfolios and Specifications
13.10.3 Merck KGaA Neuroprotective Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 Merck KGaA Main Business Overview
13.10.5 Merck KGaA Latest Developments
13.11 Teva Pharmaceutical Industries Ltd
13.11.1 Teva Pharmaceutical Industries Ltd Company Information
13.11.2 Teva Pharmaceutical Industries Ltd Neuroprotective Drugs Product Portfolios and Specifications
13.11.3 Teva Pharmaceutical Industries Ltd Neuroprotective Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 Teva Pharmaceutical Industries Ltd Main Business Overview
13.11.5 Teva Pharmaceutical Industries Ltd Latest Developments
13.12 Novartis
13.12.1 Novartis Company Information
13.12.2 Novartis Neuroprotective Drugs Product Portfolios and Specifications
13.12.3 Novartis Neuroprotective Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.12.4 Novartis Main Business Overview
13.12.5 Novartis Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Neuroprotective Drugs Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. Neuroprotective Drugs Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Cholinesterase inhibitors
Table 4. Major Players of Anti-inflammatory
Table 5. Major Players of Others
Table 6. Global Neuroprotective Drugs Sales by Type (2020-2025) & (MT)
Table 7. Global Neuroprotective Drugs Sales Market Share by Type (2020-2025)
Table 8. Global Neuroprotective Drugs Revenue by Type (2020-2025) & ($ million)
Table 9. Global Neuroprotective Drugs Revenue Market Share by Type (2020-2025)
Table 10. Global Neuroprotective Drugs Sale Price by Type (2020-2025) & (USD/Kg)
Table 11. Global Neuroprotective Drugs Sale by Application (2020-2025) & (MT)
Table 12. Global Neuroprotective Drugs Sale Market Share by Application (2020-2025)
Table 13. Global Neuroprotective Drugs Revenue by Application (2020-2025) & ($ million)
Table 14. Global Neuroprotective Drugs Revenue Market Share by Application (2020-2025)
Table 15. Global Neuroprotective Drugs Sale Price by Application (2020-2025) & (USD/Kg)
Table 16. Global Neuroprotective Drugs Sales by Company (2020-2025) & (MT)
Table 17. Global Neuroprotective Drugs Sales Market Share by Company (2020-2025)
Table 18. Global Neuroprotective Drugs Revenue by Company (2020-2025) & ($ millions)
Table 19. Global Neuroprotective Drugs Revenue Market Share by Company (2020-2025)
Table 20. Global Neuroprotective Drugs Sale Price by Company (2020-2025) & (USD/Kg)
Table 21. Key Manufacturers Neuroprotective Drugs Producing Area Distribution and Sales Area
Table 22. Players Neuroprotective Drugs Products Offered
Table 23. Neuroprotective Drugs Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 24. New Products and Potential Entrants
Table 25. Market M&A Activity & Strategy
Table 26. Global Neuroprotective Drugs Sales by Geographic Region (2020-2025) & (MT)
Table 27. Global Neuroprotective Drugs Sales Market Share Geographic Region (2020-2025)
Table 28. Global Neuroprotective Drugs Revenue by Geographic Region (2020-2025) & ($ millions)
Table 29. Global Neuroprotective Drugs Revenue Market Share by Geographic Region (2020-2025)
Table 30. Global Neuroprotective Drugs Sales by Country/Region (2020-2025) & (MT)
Table 31. Global Neuroprotective Drugs Sales Market Share by Country/Region (2020-2025)
Table 32. Global Neuroprotective Drugs Revenue by Country/Region (2020-2025) & ($ millions)
Table 33. Global Neuroprotective Drugs Revenue Market Share by Country/Region (2020-2025)
Table 34. Americas Neuroprotective Drugs Sales by Country (2020-2025) & (MT)
Table 35. Americas Neuroprotective Drugs Sales Market Share by Country (2020-2025)
Table 36. Americas Neuroprotective Drugs Revenue by Country (2020-2025) & ($ millions)
Table 37. Americas Neuroprotective Drugs Sales by Type (2020-2025) & (MT)
Table 38. Americas Neuroprotective Drugs Sales by Application (2020-2025) & (MT)
Table 39. APAC Neuroprotective Drugs Sales by Region (2020-2025) & (MT)
Table 40. APAC Neuroprotective Drugs Sales Market Share by Region (2020-2025)
Table 41. APAC Neuroprotective Drugs Revenue by Region (2020-2025) & ($ millions)
Table 42. APAC Neuroprotective Drugs Sales by Type (2020-2025) & (MT)
Table 43. APAC Neuroprotective Drugs Sales by Application (2020-2025) & (MT)
Table 44. Europe Neuroprotective Drugs Sales by Country (2020-2025) & (MT)
Table 45. Europe Neuroprotective Drugs Revenue by Country (2020-2025) & ($ millions)
Table 46. Europe Neuroprotective Drugs Sales by Type (2020-2025) & (MT)
Table 47. Europe Neuroprotective Drugs Sales by Application (2020-2025) & (MT)
Table 48. Middle East & Africa Neuroprotective Drugs Sales by Country (2020-2025) & (MT)
Table 49. Middle East & Africa Neuroprotective Drugs Revenue Market Share by Country (2020-2025)
Table 50. Middle East & Africa Neuroprotective Drugs Sales by Type (2020-2025) & (MT)
Table 51. Middle East & Africa Neuroprotective Drugs Sales by Application (2020-2025) & (MT)
Table 52. Key Market Drivers & Growth Opportunities of Neuroprotective Drugs
Table 53. Key Market Challenges & Risks of Neuroprotective Drugs
Table 54. Key Industry Trends of Neuroprotective Drugs
Table 55. Neuroprotective Drugs Raw Material
Table 56. Key Suppliers of Raw Materials
Table 57. Neuroprotective Drugs Distributors List
Table 58. Neuroprotective Drugs Customer List
Table 59. Global Neuroprotective Drugs Sales Forecast by Region (2026-2031) & (MT)
Table 60. Global Neuroprotective Drugs Revenue Forecast by Region (2026-2031) & ($ millions)
Table 61. Americas Neuroprotective Drugs Sales Forecast by Country (2026-2031) & (MT)
Table 62. Americas Neuroprotective Drugs Annual Revenue Forecast by Country (2026-2031) & ($ millions)
Table 63. APAC Neuroprotective Drugs Sales Forecast by Region (2026-2031) & (MT)
Table 64. APAC Neuroprotective Drugs Annual Revenue Forecast by Region (2026-2031) & ($ millions)
Table 65. Europe Neuroprotective Drugs Sales Forecast by Country (2026-2031) & (MT)
Table 66. Europe Neuroprotective Drugs Revenue Forecast by Country (2026-2031) & ($ millions)
Table 67. Middle East & Africa Neuroprotective Drugs Sales Forecast by Country (2026-2031) & (MT)
Table 68. Middle East & Africa Neuroprotective Drugs Revenue Forecast by Country (2026-2031) & ($ millions)
Table 69. Global Neuroprotective Drugs Sales Forecast by Type (2026-2031) & (MT)
Table 70. Global Neuroprotective Drugs Revenue Forecast by Type (2026-2031) & ($ millions)
Table 71. Global Neuroprotective Drugs Sales Forecast by Application (2026-2031) & (MT)
Table 72. Global Neuroprotective Drugs Revenue Forecast by Application (2026-2031) & ($ millions)
Table 73. Genervon Basic Information, Neuroprotective Drugs Manufacturing Base, Sales Area and Its Competitors
Table 74. Genervon Neuroprotective Drugs Product Portfolios and Specifications
Table 75. Genervon Neuroprotective Drugs Sales (MT), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2020-2025)
Table 76. Genervon Main Business
Table 77. Genervon Latest Developments
Table 78. NeuroVive Pharmaceutical Basic Information, Neuroprotective Drugs Manufacturing Base, Sales Area and Its Competitors
Table 79. NeuroVive Pharmaceutical Neuroprotective Drugs Product Portfolios and Specifications
Table 80. NeuroVive Pharmaceutical Neuroprotective Drugs Sales (MT), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2020-2025)
Table 81. NeuroVive Pharmaceutical Main Business
Table 82. NeuroVive Pharmaceutical Latest Developments
Table 83. Ceregene Basic Information, Neuroprotective Drugs Manufacturing Base, Sales Area and Its Competitors
Table 84. Ceregene Neuroprotective Drugs Product Portfolios and Specifications
Table 85. Ceregene Neuroprotective Drugs Sales (MT), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2020-2025)
Table 86. Ceregene Main Business
Table 87. Ceregene Latest Developments
Table 88. BHR Pharma Basic Information, Neuroprotective Drugs Manufacturing Base, Sales Area and Its Competitors
Table 89. BHR Pharma Neuroprotective Drugs Product Portfolios and Specifications
Table 90. BHR Pharma Neuroprotective Drugs Sales (MT), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2020-2025)
Table 91. BHR Pharma Main Business
Table 92. BHR Pharma Latest Developments
Table 93. Neuren Pharmaceuticals Basic Information, Neuroprotective Drugs Manufacturing Base, Sales Area and Its Competitors
Table 94. Neuren Pharmaceuticals Neuroprotective Drugs Product Portfolios and Specifications
Table 95. Neuren Pharmaceuticals Neuroprotective Drugs Sales (MT), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2020-2025)
Table 96. Neuren Pharmaceuticals Main Business
Table 97. Neuren Pharmaceuticals Latest Developments
Table 98. Allon therapeutics Basic Information, Neuroprotective Drugs Manufacturing Base, Sales Area and Its Competitors
Table 99. Allon therapeutics Neuroprotective Drugs Product Portfolios and Specifications
Table 100. Allon therapeutics Neuroprotective Drugs Sales (MT), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2020-2025)
Table 101. Allon therapeutics Main Business
Table 102. Allon therapeutics Latest Developments
Table 103. Bionure Basic Information, Neuroprotective Drugs Manufacturing Base, Sales Area and Its Competitors
Table 104. Bionure Neuroprotective Drugs Product Portfolios and Specifications
Table 105. Bionure Neuroprotective Drugs Sales (MT), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2020-2025)
Table 106. Bionure Main Business
Table 107. Bionure Latest Developments
Table 108. AstraZeneca Basic Information, Neuroprotective Drugs Manufacturing Base, Sales Area and Its Competitors
Table 109. AstraZeneca Neuroprotective Drugs Product Portfolios and Specifications
Table 110. AstraZeneca Neuroprotective Drugs Sales (MT), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2020-2025)
Table 111. AstraZeneca Main Business
Table 112. AstraZeneca Latest Developments
Table 113. Biogen Basic Information, Neuroprotective Drugs Manufacturing Base, Sales Area and Its Competitors
Table 114. Biogen Neuroprotective Drugs Product Portfolios and Specifications
Table 115. Biogen Neuroprotective Drugs Sales (MT), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2020-2025)
Table 116. Biogen Main Business
Table 117. Biogen Latest Developments
Table 118. Merck KGaA Basic Information, Neuroprotective Drugs Manufacturing Base, Sales Area and Its Competitors
Table 119. Merck KGaA Neuroprotective Drugs Product Portfolios and Specifications
Table 120. Merck KGaA Neuroprotective Drugs Sales (MT), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2020-2025)
Table 121. Merck KGaA Main Business
Table 122. Merck KGaA Latest Developments
Table 123. Teva Pharmaceutical Industries Ltd Basic Information, Neuroprotective Drugs Manufacturing Base, Sales Area and Its Competitors
Table 124. Teva Pharmaceutical Industries Ltd Neuroprotective Drugs Product Portfolios and Specifications
Table 125. Teva Pharmaceutical Industries Ltd Neuroprotective Drugs Sales (MT), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2020-2025)
Table 126. Teva Pharmaceutical Industries Ltd Main Business
Table 127. Teva Pharmaceutical Industries Ltd Latest Developments
Table 128. Novartis Basic Information, Neuroprotective Drugs Manufacturing Base, Sales Area and Its Competitors
Table 129. Novartis Neuroprotective Drugs Product Portfolios and Specifications
Table 130. Novartis Neuroprotective Drugs Sales (MT), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2020-2025)
Table 131. Novartis Main Business
Table 132. Novartis Latest Developments
Table 1. Neuroprotective Drugs Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. Neuroprotective Drugs Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Cholinesterase inhibitors
Table 4. Major Players of Anti-inflammatory
Table 5. Major Players of Others
Table 6. Global Neuroprotective Drugs Sales by Type (2020-2025) & (MT)
Table 7. Global Neuroprotective Drugs Sales Market Share by Type (2020-2025)
Table 8. Global Neuroprotective Drugs Revenue by Type (2020-2025) & ($ million)
Table 9. Global Neuroprotective Drugs Revenue Market Share by Type (2020-2025)
Table 10. Global Neuroprotective Drugs Sale Price by Type (2020-2025) & (USD/Kg)
Table 11. Global Neuroprotective Drugs Sale by Application (2020-2025) & (MT)
Table 12. Global Neuroprotective Drugs Sale Market Share by Application (2020-2025)
Table 13. Global Neuroprotective Drugs Revenue by Application (2020-2025) & ($ million)
Table 14. Global Neuroprotective Drugs Revenue Market Share by Application (2020-2025)
Table 15. Global Neuroprotective Drugs Sale Price by Application (2020-2025) & (USD/Kg)
Table 16. Global Neuroprotective Drugs Sales by Company (2020-2025) & (MT)
Table 17. Global Neuroprotective Drugs Sales Market Share by Company (2020-2025)
Table 18. Global Neuroprotective Drugs Revenue by Company (2020-2025) & ($ millions)
Table 19. Global Neuroprotective Drugs Revenue Market Share by Company (2020-2025)
Table 20. Global Neuroprotective Drugs Sale Price by Company (2020-2025) & (USD/Kg)
Table 21. Key Manufacturers Neuroprotective Drugs Producing Area Distribution and Sales Area
Table 22. Players Neuroprotective Drugs Products Offered
Table 23. Neuroprotective Drugs Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 24. New Products and Potential Entrants
Table 25. Market M&A Activity & Strategy
Table 26. Global Neuroprotective Drugs Sales by Geographic Region (2020-2025) & (MT)
Table 27. Global Neuroprotective Drugs Sales Market Share Geographic Region (2020-2025)
Table 28. Global Neuroprotective Drugs Revenue by Geographic Region (2020-2025) & ($ millions)
Table 29. Global Neuroprotective Drugs Revenue Market Share by Geographic Region (2020-2025)
Table 30. Global Neuroprotective Drugs Sales by Country/Region (2020-2025) & (MT)
Table 31. Global Neuroprotective Drugs Sales Market Share by Country/Region (2020-2025)
Table 32. Global Neuroprotective Drugs Revenue by Country/Region (2020-2025) & ($ millions)
Table 33. Global Neuroprotective Drugs Revenue Market Share by Country/Region (2020-2025)
Table 34. Americas Neuroprotective Drugs Sales by Country (2020-2025) & (MT)
Table 35. Americas Neuroprotective Drugs Sales Market Share by Country (2020-2025)
Table 36. Americas Neuroprotective Drugs Revenue by Country (2020-2025) & ($ millions)
Table 37. Americas Neuroprotective Drugs Sales by Type (2020-2025) & (MT)
Table 38. Americas Neuroprotective Drugs Sales by Application (2020-2025) & (MT)
Table 39. APAC Neuroprotective Drugs Sales by Region (2020-2025) & (MT)
Table 40. APAC Neuroprotective Drugs Sales Market Share by Region (2020-2025)
Table 41. APAC Neuroprotective Drugs Revenue by Region (2020-2025) & ($ millions)
Table 42. APAC Neuroprotective Drugs Sales by Type (2020-2025) & (MT)
Table 43. APAC Neuroprotective Drugs Sales by Application (2020-2025) & (MT)
Table 44. Europe Neuroprotective Drugs Sales by Country (2020-2025) & (MT)
Table 45. Europe Neuroprotective Drugs Revenue by Country (2020-2025) & ($ millions)
Table 46. Europe Neuroprotective Drugs Sales by Type (2020-2025) & (MT)
Table 47. Europe Neuroprotective Drugs Sales by Application (2020-2025) & (MT)
Table 48. Middle East & Africa Neuroprotective Drugs Sales by Country (2020-2025) & (MT)
Table 49. Middle East & Africa Neuroprotective Drugs Revenue Market Share by Country (2020-2025)
Table 50. Middle East & Africa Neuroprotective Drugs Sales by Type (2020-2025) & (MT)
Table 51. Middle East & Africa Neuroprotective Drugs Sales by Application (2020-2025) & (MT)
Table 52. Key Market Drivers & Growth Opportunities of Neuroprotective Drugs
Table 53. Key Market Challenges & Risks of Neuroprotective Drugs
Table 54. Key Industry Trends of Neuroprotective Drugs
Table 55. Neuroprotective Drugs Raw Material
Table 56. Key Suppliers of Raw Materials
Table 57. Neuroprotective Drugs Distributors List
Table 58. Neuroprotective Drugs Customer List
Table 59. Global Neuroprotective Drugs Sales Forecast by Region (2026-2031) & (MT)
Table 60. Global Neuroprotective Drugs Revenue Forecast by Region (2026-2031) & ($ millions)
Table 61. Americas Neuroprotective Drugs Sales Forecast by Country (2026-2031) & (MT)
Table 62. Americas Neuroprotective Drugs Annual Revenue Forecast by Country (2026-2031) & ($ millions)
Table 63. APAC Neuroprotective Drugs Sales Forecast by Region (2026-2031) & (MT)
Table 64. APAC Neuroprotective Drugs Annual Revenue Forecast by Region (2026-2031) & ($ millions)
Table 65. Europe Neuroprotective Drugs Sales Forecast by Country (2026-2031) & (MT)
Table 66. Europe Neuroprotective Drugs Revenue Forecast by Country (2026-2031) & ($ millions)
Table 67. Middle East & Africa Neuroprotective Drugs Sales Forecast by Country (2026-2031) & (MT)
Table 68. Middle East & Africa Neuroprotective Drugs Revenue Forecast by Country (2026-2031) & ($ millions)
Table 69. Global Neuroprotective Drugs Sales Forecast by Type (2026-2031) & (MT)
Table 70. Global Neuroprotective Drugs Revenue Forecast by Type (2026-2031) & ($ millions)
Table 71. Global Neuroprotective Drugs Sales Forecast by Application (2026-2031) & (MT)
Table 72. Global Neuroprotective Drugs Revenue Forecast by Application (2026-2031) & ($ millions)
Table 73. Genervon Basic Information, Neuroprotective Drugs Manufacturing Base, Sales Area and Its Competitors
Table 74. Genervon Neuroprotective Drugs Product Portfolios and Specifications
Table 75. Genervon Neuroprotective Drugs Sales (MT), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2020-2025)
Table 76. Genervon Main Business
Table 77. Genervon Latest Developments
Table 78. NeuroVive Pharmaceutical Basic Information, Neuroprotective Drugs Manufacturing Base, Sales Area and Its Competitors
Table 79. NeuroVive Pharmaceutical Neuroprotective Drugs Product Portfolios and Specifications
Table 80. NeuroVive Pharmaceutical Neuroprotective Drugs Sales (MT), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2020-2025)
Table 81. NeuroVive Pharmaceutical Main Business
Table 82. NeuroVive Pharmaceutical Latest Developments
Table 83. Ceregene Basic Information, Neuroprotective Drugs Manufacturing Base, Sales Area and Its Competitors
Table 84. Ceregene Neuroprotective Drugs Product Portfolios and Specifications
Table 85. Ceregene Neuroprotective Drugs Sales (MT), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2020-2025)
Table 86. Ceregene Main Business
Table 87. Ceregene Latest Developments
Table 88. BHR Pharma Basic Information, Neuroprotective Drugs Manufacturing Base, Sales Area and Its Competitors
Table 89. BHR Pharma Neuroprotective Drugs Product Portfolios and Specifications
Table 90. BHR Pharma Neuroprotective Drugs Sales (MT), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2020-2025)
Table 91. BHR Pharma Main Business
Table 92. BHR Pharma Latest Developments
Table 93. Neuren Pharmaceuticals Basic Information, Neuroprotective Drugs Manufacturing Base, Sales Area and Its Competitors
Table 94. Neuren Pharmaceuticals Neuroprotective Drugs Product Portfolios and Specifications
Table 95. Neuren Pharmaceuticals Neuroprotective Drugs Sales (MT), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2020-2025)
Table 96. Neuren Pharmaceuticals Main Business
Table 97. Neuren Pharmaceuticals Latest Developments
Table 98. Allon therapeutics Basic Information, Neuroprotective Drugs Manufacturing Base, Sales Area and Its Competitors
Table 99. Allon therapeutics Neuroprotective Drugs Product Portfolios and Specifications
Table 100. Allon therapeutics Neuroprotective Drugs Sales (MT), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2020-2025)
Table 101. Allon therapeutics Main Business
Table 102. Allon therapeutics Latest Developments
Table 103. Bionure Basic Information, Neuroprotective Drugs Manufacturing Base, Sales Area and Its Competitors
Table 104. Bionure Neuroprotective Drugs Product Portfolios and Specifications
Table 105. Bionure Neuroprotective Drugs Sales (MT), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2020-2025)
Table 106. Bionure Main Business
Table 107. Bionure Latest Developments
Table 108. AstraZeneca Basic Information, Neuroprotective Drugs Manufacturing Base, Sales Area and Its Competitors
Table 109. AstraZeneca Neuroprotective Drugs Product Portfolios and Specifications
Table 110. AstraZeneca Neuroprotective Drugs Sales (MT), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2020-2025)
Table 111. AstraZeneca Main Business
Table 112. AstraZeneca Latest Developments
Table 113. Biogen Basic Information, Neuroprotective Drugs Manufacturing Base, Sales Area and Its Competitors
Table 114. Biogen Neuroprotective Drugs Product Portfolios and Specifications
Table 115. Biogen Neuroprotective Drugs Sales (MT), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2020-2025)
Table 116. Biogen Main Business
Table 117. Biogen Latest Developments
Table 118. Merck KGaA Basic Information, Neuroprotective Drugs Manufacturing Base, Sales Area and Its Competitors
Table 119. Merck KGaA Neuroprotective Drugs Product Portfolios and Specifications
Table 120. Merck KGaA Neuroprotective Drugs Sales (MT), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2020-2025)
Table 121. Merck KGaA Main Business
Table 122. Merck KGaA Latest Developments
Table 123. Teva Pharmaceutical Industries Ltd Basic Information, Neuroprotective Drugs Manufacturing Base, Sales Area and Its Competitors
Table 124. Teva Pharmaceutical Industries Ltd Neuroprotective Drugs Product Portfolios and Specifications
Table 125. Teva Pharmaceutical Industries Ltd Neuroprotective Drugs Sales (MT), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2020-2025)
Table 126. Teva Pharmaceutical Industries Ltd Main Business
Table 127. Teva Pharmaceutical Industries Ltd Latest Developments
Table 128. Novartis Basic Information, Neuroprotective Drugs Manufacturing Base, Sales Area and Its Competitors
Table 129. Novartis Neuroprotective Drugs Product Portfolios and Specifications
Table 130. Novartis Neuroprotective Drugs Sales (MT), Revenue ($ Million), Price (USD/Kg) and Gross Margin (2020-2025)
Table 131. Novartis Main Business
Table 132. Novartis Latest Developments
LIST OF FIGURES
Figure 1. Picture of Neuroprotective Drugs
Figure 2. Neuroprotective Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Neuroprotective Drugs Sales Growth Rate 2020-2031 (MT)
Figure 7. Global Neuroprotective Drugs Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. Neuroprotective Drugs Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. Neuroprotective Drugs Sales Market Share by Country/Region (2024)
Figure 10. Neuroprotective Drugs Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of Cholinesterase inhibitors
Figure 12. Product Picture of Anti-inflammatory
Figure 13. Product Picture of Others
Figure 14. Global Neuroprotective Drugs Sales Market Share by Type in 2025
Figure 15. Global Neuroprotective Drugs Revenue Market Share by Type (2020-2025)
Figure 16. Neuroprotective Drugs Consumed in Alzheimer's disease
Figure 17. Global Neuroprotective Drugs Market: Alzheimer's disease (2020-2025) & (MT)
Figure 18. Neuroprotective Drugs Consumed in Parkinson's disease
Figure 19. Global Neuroprotective Drugs Market: Parkinson's disease (2020-2025) & (MT)
Figure 20. Neuroprotective Drugs Consumed in Others
Figure 21. Global Neuroprotective Drugs Market: Others (2020-2025) & (MT)
Figure 22. Global Neuroprotective Drugs Sale Market Share by Application (2024)
Figure 23. Global Neuroprotective Drugs Revenue Market Share by Application in 2025
Figure 24. Neuroprotective Drugs Sales by Company in 2025 (MT)
Figure 25. Global Neuroprotective Drugs Sales Market Share by Company in 2025
Figure 26. Neuroprotective Drugs Revenue by Company in 2025 ($ millions)
Figure 27. Global Neuroprotective Drugs Revenue Market Share by Company in 2025
Figure 28. Global Neuroprotective Drugs Sales Market Share by Geographic Region (2020-2025)
Figure 29. Global Neuroprotective Drugs Revenue Market Share by Geographic Region in 2025
Figure 30. Americas Neuroprotective Drugs Sales 2020-2025 (MT)
Figure 31. Americas Neuroprotective Drugs Revenue 2020-2025 ($ millions)
Figure 32. APAC Neuroprotective Drugs Sales 2020-2025 (MT)
Figure 33. APAC Neuroprotective Drugs Revenue 2020-2025 ($ millions)
Figure 34. Europe Neuroprotective Drugs Sales 2020-2025 (MT)
Figure 35. Europe Neuroprotective Drugs Revenue 2020-2025 ($ millions)
Figure 36. Middle East & Africa Neuroprotective Drugs Sales 2020-2025 (MT)
Figure 37. Middle East & Africa Neuroprotective Drugs Revenue 2020-2025 ($ millions)
Figure 38. Americas Neuroprotective Drugs Sales Market Share by Country in 2025
Figure 39. Americas Neuroprotective Drugs Revenue Market Share by Country (2020-2025)
Figure 40. Americas Neuroprotective Drugs Sales Market Share by Type (2020-2025)
Figure 41. Americas Neuroprotective Drugs Sales Market Share by Application (2020-2025)
Figure 42. United States Neuroprotective Drugs Revenue Growth 2020-2025 ($ millions)
Figure 43. Canada Neuroprotective Drugs Revenue Growth 2020-2025 ($ millions)
Figure 44. Mexico Neuroprotective Drugs Revenue Growth 2020-2025 ($ millions)
Figure 45. Brazil Neuroprotective Drugs Revenue Growth 2020-2025 ($ millions)
Figure 46. APAC Neuroprotective Drugs Sales Market Share by Region in 2025
Figure 47. APAC Neuroprotective Drugs Revenue Market Share by Region (2020-2025)
Figure 48. APAC Neuroprotective Drugs Sales Market Share by Type (2020-2025)
Figure 49. APAC Neuroprotective Drugs Sales Market Share by Application (2020-2025)
Figure 50. China Neuroprotective Drugs Revenue Growth 2020-2025 ($ millions)
Figure 51. Japan Neuroprotective Drugs Revenue Growth 2020-2025 ($ millions)
Figure 52. South Korea Neuroprotective Drugs Revenue Growth 2020-2025 ($ millions)
Figure 53. Southeast Asia Neuroprotective Drugs Revenue Growth 2020-2025 ($ millions)
Figure 54. India Neuroprotective Drugs Revenue Growth 2020-2025 ($ millions)
Figure 55. Australia Neuroprotective Drugs Revenue Growth 2020-2025 ($ millions)
Figure 56. China Taiwan Neuroprotective Drugs Revenue Growth 2020-2025 ($ millions)
Figure 57. Europe Neuroprotective Drugs Sales Market Share by Country in 2025
Figure 58. Europe Neuroprotective Drugs Revenue Market Share by Country (2020-2025)
Figure 59. Europe Neuroprotective Drugs Sales Market Share by Type (2020-2025)
Figure 60. Europe Neuroprotective Drugs Sales Market Share by Application (2020-2025)
Figure 61. Germany Neuroprotective Drugs Revenue Growth 2020-2025 ($ millions)
Figure 62. France Neuroprotective Drugs Revenue Growth 2020-2025 ($ millions)
Figure 63. UK Neuroprotective Drugs Revenue Growth 2020-2025 ($ millions)
Figure 64. Italy Neuroprotective Drugs Revenue Growth 2020-2025 ($ millions)
Figure 65. Russia Neuroprotective Drugs Revenue Growth 2020-2025 ($ millions)
Figure 66. Middle East & Africa Neuroprotective Drugs Sales Market Share by Country (2020-2025)
Figure 67. Middle East & Africa Neuroprotective Drugs Sales Market Share by Type (2020-2025)
Figure 68. Middle East & Africa Neuroprotective Drugs Sales Market Share by Application (2020-2025)
Figure 69. Egypt Neuroprotective Drugs Revenue Growth 2020-2025 ($ millions)
Figure 70. South Africa Neuroprotective Drugs Revenue Growth 2020-2025 ($ millions)
Figure 71. Israel Neuroprotective Drugs Revenue Growth 2020-2025 ($ millions)
Figure 72. Turkey Neuroprotective Drugs Revenue Growth 2020-2025 ($ millions)
Figure 73. GCC Countries Neuroprotective Drugs Revenue Growth 2020-2025 ($ millions)
Figure 74. Manufacturing Cost Structure Analysis of Neuroprotective Drugs in 2025
Figure 75. Manufacturing Process Analysis of Neuroprotective Drugs
Figure 76. Industry Chain Structure of Neuroprotective Drugs
Figure 77. Channels of Distribution
Figure 78. Global Neuroprotective Drugs Sales Market Forecast by Region (2026-2031)
Figure 79. Global Neuroprotective Drugs Revenue Market Share Forecast by Region (2026-2031)
Figure 80. Global Neuroprotective Drugs Sales Market Share Forecast by Type (2026-2031)
Figure 81. Global Neuroprotective Drugs Revenue Market Share Forecast by Type (2026-2031)
Figure 82. Global Neuroprotective Drugs Sales Market Share Forecast by Application (2026-2031)
Figure 83. Global Neuroprotective Drugs Revenue Market Share Forecast by Application (2026-2031)
Figure 1. Picture of Neuroprotective Drugs
Figure 2. Neuroprotective Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Neuroprotective Drugs Sales Growth Rate 2020-2031 (MT)
Figure 7. Global Neuroprotective Drugs Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. Neuroprotective Drugs Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. Neuroprotective Drugs Sales Market Share by Country/Region (2024)
Figure 10. Neuroprotective Drugs Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of Cholinesterase inhibitors
Figure 12. Product Picture of Anti-inflammatory
Figure 13. Product Picture of Others
Figure 14. Global Neuroprotective Drugs Sales Market Share by Type in 2025
Figure 15. Global Neuroprotective Drugs Revenue Market Share by Type (2020-2025)
Figure 16. Neuroprotective Drugs Consumed in Alzheimer's disease
Figure 17. Global Neuroprotective Drugs Market: Alzheimer's disease (2020-2025) & (MT)
Figure 18. Neuroprotective Drugs Consumed in Parkinson's disease
Figure 19. Global Neuroprotective Drugs Market: Parkinson's disease (2020-2025) & (MT)
Figure 20. Neuroprotective Drugs Consumed in Others
Figure 21. Global Neuroprotective Drugs Market: Others (2020-2025) & (MT)
Figure 22. Global Neuroprotective Drugs Sale Market Share by Application (2024)
Figure 23. Global Neuroprotective Drugs Revenue Market Share by Application in 2025
Figure 24. Neuroprotective Drugs Sales by Company in 2025 (MT)
Figure 25. Global Neuroprotective Drugs Sales Market Share by Company in 2025
Figure 26. Neuroprotective Drugs Revenue by Company in 2025 ($ millions)
Figure 27. Global Neuroprotective Drugs Revenue Market Share by Company in 2025
Figure 28. Global Neuroprotective Drugs Sales Market Share by Geographic Region (2020-2025)
Figure 29. Global Neuroprotective Drugs Revenue Market Share by Geographic Region in 2025
Figure 30. Americas Neuroprotective Drugs Sales 2020-2025 (MT)
Figure 31. Americas Neuroprotective Drugs Revenue 2020-2025 ($ millions)
Figure 32. APAC Neuroprotective Drugs Sales 2020-2025 (MT)
Figure 33. APAC Neuroprotective Drugs Revenue 2020-2025 ($ millions)
Figure 34. Europe Neuroprotective Drugs Sales 2020-2025 (MT)
Figure 35. Europe Neuroprotective Drugs Revenue 2020-2025 ($ millions)
Figure 36. Middle East & Africa Neuroprotective Drugs Sales 2020-2025 (MT)
Figure 37. Middle East & Africa Neuroprotective Drugs Revenue 2020-2025 ($ millions)
Figure 38. Americas Neuroprotective Drugs Sales Market Share by Country in 2025
Figure 39. Americas Neuroprotective Drugs Revenue Market Share by Country (2020-2025)
Figure 40. Americas Neuroprotective Drugs Sales Market Share by Type (2020-2025)
Figure 41. Americas Neuroprotective Drugs Sales Market Share by Application (2020-2025)
Figure 42. United States Neuroprotective Drugs Revenue Growth 2020-2025 ($ millions)
Figure 43. Canada Neuroprotective Drugs Revenue Growth 2020-2025 ($ millions)
Figure 44. Mexico Neuroprotective Drugs Revenue Growth 2020-2025 ($ millions)
Figure 45. Brazil Neuroprotective Drugs Revenue Growth 2020-2025 ($ millions)
Figure 46. APAC Neuroprotective Drugs Sales Market Share by Region in 2025
Figure 47. APAC Neuroprotective Drugs Revenue Market Share by Region (2020-2025)
Figure 48. APAC Neuroprotective Drugs Sales Market Share by Type (2020-2025)
Figure 49. APAC Neuroprotective Drugs Sales Market Share by Application (2020-2025)
Figure 50. China Neuroprotective Drugs Revenue Growth 2020-2025 ($ millions)
Figure 51. Japan Neuroprotective Drugs Revenue Growth 2020-2025 ($ millions)
Figure 52. South Korea Neuroprotective Drugs Revenue Growth 2020-2025 ($ millions)
Figure 53. Southeast Asia Neuroprotective Drugs Revenue Growth 2020-2025 ($ millions)
Figure 54. India Neuroprotective Drugs Revenue Growth 2020-2025 ($ millions)
Figure 55. Australia Neuroprotective Drugs Revenue Growth 2020-2025 ($ millions)
Figure 56. China Taiwan Neuroprotective Drugs Revenue Growth 2020-2025 ($ millions)
Figure 57. Europe Neuroprotective Drugs Sales Market Share by Country in 2025
Figure 58. Europe Neuroprotective Drugs Revenue Market Share by Country (2020-2025)
Figure 59. Europe Neuroprotective Drugs Sales Market Share by Type (2020-2025)
Figure 60. Europe Neuroprotective Drugs Sales Market Share by Application (2020-2025)
Figure 61. Germany Neuroprotective Drugs Revenue Growth 2020-2025 ($ millions)
Figure 62. France Neuroprotective Drugs Revenue Growth 2020-2025 ($ millions)
Figure 63. UK Neuroprotective Drugs Revenue Growth 2020-2025 ($ millions)
Figure 64. Italy Neuroprotective Drugs Revenue Growth 2020-2025 ($ millions)
Figure 65. Russia Neuroprotective Drugs Revenue Growth 2020-2025 ($ millions)
Figure 66. Middle East & Africa Neuroprotective Drugs Sales Market Share by Country (2020-2025)
Figure 67. Middle East & Africa Neuroprotective Drugs Sales Market Share by Type (2020-2025)
Figure 68. Middle East & Africa Neuroprotective Drugs Sales Market Share by Application (2020-2025)
Figure 69. Egypt Neuroprotective Drugs Revenue Growth 2020-2025 ($ millions)
Figure 70. South Africa Neuroprotective Drugs Revenue Growth 2020-2025 ($ millions)
Figure 71. Israel Neuroprotective Drugs Revenue Growth 2020-2025 ($ millions)
Figure 72. Turkey Neuroprotective Drugs Revenue Growth 2020-2025 ($ millions)
Figure 73. GCC Countries Neuroprotective Drugs Revenue Growth 2020-2025 ($ millions)
Figure 74. Manufacturing Cost Structure Analysis of Neuroprotective Drugs in 2025
Figure 75. Manufacturing Process Analysis of Neuroprotective Drugs
Figure 76. Industry Chain Structure of Neuroprotective Drugs
Figure 77. Channels of Distribution
Figure 78. Global Neuroprotective Drugs Sales Market Forecast by Region (2026-2031)
Figure 79. Global Neuroprotective Drugs Revenue Market Share Forecast by Region (2026-2031)
Figure 80. Global Neuroprotective Drugs Sales Market Share Forecast by Type (2026-2031)
Figure 81. Global Neuroprotective Drugs Revenue Market Share Forecast by Type (2026-2031)
Figure 82. Global Neuroprotective Drugs Sales Market Share Forecast by Application (2026-2031)
Figure 83. Global Neuroprotective Drugs Revenue Market Share Forecast by Application (2026-2031)
